TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07870330: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

Sponsor: ModernaTX, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,712,580

Rescue Site Savings

+$1,126,080

Unlock Full NCT07870330 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07870330 Rescue Dossier →